{"cluster": 36, "subcluster": 20, "abstract_summ": "RESULTS COVID-19 patients are more fragile with underlying metabolic illness, including hypertension, cardiovascular disease, type 2 diabetes, chronic lung diseases (e.g., asthma, chronic obstructive pulmonary disease, and emphysema), and metabolic syndrome.Case series have reported that people with obesity experience more severe coronavirus disease 2019 (COVID-19).It is widely believed that infection with the SARS-CoV2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease.After infecting the host cells, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause a hyperinflammatory reaction through the excessive release of cytokines, a condition known as \u201ccytokine storm,\u201d while inducing lymphopenia and a disrupted immune response.CONCLUSION: Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese.", "title_summ": "The gut lymphatics - lung axis hypothesisThe impact of nutrition on COVID-19 susceptibility and long-term consequencesObesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomesInfluenza and obesity: its odd relationship and the lessons for COVID-19 pandemicMelatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspectsDoes high cardiorespiratory fitness confer some protection against pro\u2010inflammatory responses after infection by SARS\u2010CoV\u20102?Mechanism of inflammatory response in associated comorbidities in COVID-19Proper Management of People with Obesity during the COVID-19 PandemicIs Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?COVID-19 and the role of chronic inflammation in patients with obesityMetabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical CourseThe Association between Obesity and Poor Outcome after COVID-19 Indicates a Potential Therapeutic Role for MontelukastPotential Benefits and Harms of Novel Antidiabetic Drugs during COVID-19 CrisisObesity and COVID-19: A Fatal AllianceObesity, the most common comorbidity in SARS-CoV-2: is leptin the link?Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic.COVID-19 comorbidities, associated pro-coagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity?Interactions of SARS-CoV-2 infection with chronic obesity inflammation: a complex network phenomenonWhy is SARS-CoV-2 infection more severe in obese men?Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2?COVID-19 and nonalcoholic fatty liver disease: two intersecting pandemics.Cholesterol-modifying drugs in COVID-19SGLT2 inhibition and COVID-19: The road not taken.", "title_abstract_phrases": "The Association between Obesity and Poor Outcome after COVID-19 Indicates a Potential Therapeutic Role for MontelukastIt is widely believed that infection with the SARS-CoV2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease.Case series have reported that people with obesity experience more severe coronavirus disease 2019 (COVID-19).Proper Management of People with Obesity during the COVID-19 PandemicSince December 2019, countries around the world have been struggling with a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).RESULTS COVID-19 patients are more fragile with underlying metabolic illness, including hypertension, cardiovascular disease, type 2 diabetes, chronic lung diseases (e.g., asthma, chronic obstructive pulmonary disease, and emphysema), and metabolic syndrome.After infecting the host cells, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause a hyperinflammatory reaction through the excessive release of cytokines, a condition known as \u201ccytokine storm,\u201d while inducing lymphopenia and a disrupted immune response."}